Source: International Business Times
Shares of Nektar Therapeutics surged more than 19% in early Monday trading on April 20, 2026, climbing $16. 58 to $101. 44 as investors cheered positive 52-week topline results from the Phase 2b REZOLVE-AA clinical trial of the company's lead immunology candidate, rezpegaldesleukin, in patients with severe-to-very-severe alopecia areata.
Aller á la Source
Nouvelles connexes
